Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI) (PROMISE)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03986138 |
Recruitment Status :
Completed
First Posted : June 14, 2019
Last Update Posted : November 10, 2021
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Lesion in Body Region | Drug: gadopiclenol Drug: Gadobutrol 1 MMOLE/ML Intravenous Solution | Phase 3 |
The purpose of this trial is to evaluate a new gadolinium-based contrast agent (GBCA) gadopiclenol in terms of lesion visualization in patients referred for contrast-enhanced MRI of body regions.
This is a prospective, international, multi-center, randomized, double-blind, controlled and cross-over trial.
This trial will be conducted in approximately 50 centers worldwide. During the course of the trial, two MRIs will be obtained from each patient: one with gadopiclenol and one with gadobutrol. MRI evaluations will be assessed by independent off-site blinded readers.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 304 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Diagnostic |
Official Title: | Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI) |
Actual Study Start Date : | August 27, 2019 |
Actual Primary Completion Date : | December 9, 2020 |
Actual Study Completion Date : | December 9, 2020 |
Arm | Intervention/treatment |
---|---|
Experimental: gadopiclenol-enhanced MRI then gadobutrol-enhanced MRI
Cross-over design: each patient receives gadopiclenol for the first MRI and then gadobutrol for the second MRI
|
Drug: gadopiclenol
Single intravenous bolus injection Drug: Gadobutrol 1 MMOLE/ML Intravenous Solution Single intravenous bolus injection |
Experimental: gadobutrol-enhanced MRI then gadopiclenol-enhanced MRI
Cross-over design: each patient receives gadobutrol for the first MRI and then gadopiclenol for the second MRI
|
Drug: gadopiclenol
Single intravenous bolus injection Drug: Gadobutrol 1 MMOLE/ML Intravenous Solution Single intravenous bolus injection |
- Lesion visualization criteria for gadopiclenol-enhanced MRI compared to unenhanced MRI [ Time Frame: 1 day procedure ]The lesion visualization criteria is based on 3 co-primary criteria: border delineation, internal morphology and degree of contrast enhancement, assessed by independent blinded readers on the images acquired during the MRI performed with gadopiclenol for up to 3 most representative lesions
- Lesion visualization criteria for gadopiclenol-enhanced MRI compared to gadobutrol-enhanced MRI [ Time Frame: 1 day procedure ]The lesion visualization criteria is based on 3 co-primary criteria: border delineation, internal morphology and degree of contrast enhancement, assessed by independent blinded readers on the images acquired during the MRI performed with gadopiclenol and MRI performed with gadobutrol for up to 3 most representative lesions
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patient presenting with known or suspected enhancing abnormality(ies) and/or lesion(s) in at least one body region based on a previous imaging procedure performed within 12 months prior to ICF signature. US patients are restricted to the breast in compliance with local approved indications of gadobutrol.
Exclusion Criteria:
- Patient presenting with acute or chronic renal insufficiency, defined as an estimated Glomerular Filtration Rate (eGFR) < 30 mL/min/1.73 m² assessed within 1 day prior to each contrast agent administration.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03986138
Responsible Party: | Guerbet |
ClinicalTrials.gov Identifier: | NCT03986138 |
Other Study ID Numbers: |
GDX-44-011 |
First Posted: | June 14, 2019 Key Record Dates |
Last Update Posted: | November 10, 2021 |
Last Verified: | November 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |